Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147509 | 0.86 | RET (0.38) | RETKDM5ATP53SMN1; SMN2PREP | |
| SCHEMBL20147983 | 0.84 | RET (0.37) | RETKDM5ATP53SMN1; SMN2PREP | |
| SCHEMBL20158582 | 0.80 | CHRNB4 (0.34) | RETCTSKCHRNB4CHRNA3 | |
| SCHEMBL20069720 | 0.79 | SMN1; SMN2 (0.39) | RETKDM5ATP53SMN1; SMN2PREP | |
| SCHEMBL25503417 | 0.78 | RET (0.38) | RETKDM5ATP53SMN1; SMN2PREP | |
| SCHEMBL20626727 | 0.77 | RET (0.32) | RET | |
| SCHEMBL20158525 | 0.76 | SMN1; SMN2 (0.35) | RETKDM5ATP53SMN1; SMN2 | |
| SCHEMBL20147533 | 0.71 | RET (0.37) | RETKDM5ATP53SMN1; SMN2PREP | |
| SCHEMBL20070146 | 0.71 | SMN1; SMN2 (0.38) | RETKDM5ATP53SMN1; SMN2 | |
| SCHEMBL19538672 | 0.70 | PSEN1 (0.36) | PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885KDM5A 902/4885TP53 759/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885KDM5A 902/4885TP53 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.